## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.6% below STRENGTH zone (3.0-6.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($135.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Agilent and Monash University Malaysia to set up biodiscovery hub**
- Source: Yahoo | 20251208T093600 | Bullish | Relevance: 99%
-  Agilent Technologies and Monash University Malaysia (MUM) have expanded their 15-year collaboration to establish the MUM Proteomics & Metabolomics Platform (MUMPMP)-Agilent BioDiscovery Hub. This initiative aims to boost biotechnology research and innovation in the region. Agilent will provide advanced equipment, including its Revident Quadrupole Time of Flight LC/MS systems, to accelerate R&D in small and large molecule analysis within the pharmaceutical, biomedical, and molecular biology sectors.

**2. Goldman Sachs Initiates Coverage on Agilent (A) with Positive Outlook**
- Source: GuruFocus | 20251209T210814 | Bullish | Relevance: 99%
-  Goldman Sachs has initiated coverage on Agilent Technologies (A) with a "buy" rating and a price target of $170, anticipating a 19% upside. The investment bank expects Agilent to benefit from a biopharma instrument replacement cycle, industrial sector recovery, and the upcoming launch of the Infinity III HPLC. This positive outlook is supported by Agilent's consistent financial performance, strong market position, and solid financial health.

**3. Q3 Earnings Outperformers: Agilent (NYSE:A) And The Rest Of The Research Tools & Consumables Stocks**
- Source: Finviz | 20251210T110722 | Neutral | Relevance: 98%
- This article reviews the Q3 earnings performance of companies in the research tools & consumables industry. It highlights Agilent (NYSE:A) as a top performer with 9.4% year-on-year revenue growth, while also detailing the performances of Sotera Health Company (NASDAQ:SHC), Avantor (NYSE:AVTR), Danaher (NYSE:DHR), and Bio-Techne (NASDAQ:TECH). The sector overall experienced mixed results with revenues beating estimates by 1.1% but next quarter's guidance falling 1.3% below expectations.

**4. Agilent and Monash University Malaysia to set up biodiscovery hub**
- Source: Pharmaceutical Technology | 20251208T084321 | Bullish | Relevance: 98%
-  Agilent Technologies and Monash University Malaysia (MUM) have expanded their collaboration to establish the MUM Proteomics & Metabolomics Platform (MUMPMP)-Agilent BioDiscovery Hub. This initiative aims to bolster biotechnology research and innovation in the region, focusing on expediting R&D in small and large-molecule analysis. Agilent will provide advanced equipment to the hub, facilitating research programs, workshops, and scientific training.

**5. Here Are Tuesday's Top Wall Street Analyst Research Calls: Agilent, Alibaba, Delta Air Lines, Intel, JD.com, Micron Technology, Reddit and More**
- Source: 24/7 Wall St. | 20251209T131700 | Somewhat-Bullish | Relevance: 94%
-  This article details top Wall Street analyst upgrades, downgrades, and initiations from December 9, 2025, covering several major companies. It also provides a market overview for pre-market futures, Treasury bonds, oil and gas, gold, and cryptocurrency, highlighting investor anticipation of a potential Federal Reserve rate cut. The market saw stocks decrease across the board on Monday, with major indices closing negatively due to Federal Reserve uncertainty.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 21.9x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.7B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 21.9 |
| Current P/E | 24.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -3.6% (minimal 5-day change). Below STRENGTH zone by 6.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.16x) but short-term weakness (below SMA20). MACD histogram bearish (-1.39), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.65% (CS: 12) | Weak |
| RSI_14 | 44.4 | Neutral |
| MACD Histogram | -1.39 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.157x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $143.47
- **Stop Loss:** $135.65 (5.5% risk)
- **Target:** $151.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 63
- **Position Value:** $9,038.61
- **Portfolio %:** 9.04%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*